Please login to the form below
Healthcare terms - G
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare Glossary
A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W |
Healthcare terms - G
- Global Health Observatory
- Gatekeeper
- General practitioner (GP)
- Generic medicine
- Generic name
- Genome
- Geo-demographics
- Glass ceiling
- Global brand
- Global Health Index
- Global marketing
- Grey market
- Grey marketing (also called parallel importing)
- Greying, leisured, affluent, middle-aged (GLAM)
- Gross Domestic Product (GDP)
- Group dynamics
- Growth stage
- Guarantees and warranties
- Guerrilla marketing
- Guppie
- Gutter
Featured jobs
- Senior Medical Writer, MedComms Agency
-
Salary TBC
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Vice President
-
Competitive Salary Offered
-
Consultant
-
competitive salary
- Account Director or Senior Account Director
-
Salary TBC
-
Principal Medical Writer
-
£48 - 58, 000 according to skills and experience benefits
- Director of Scientific Services, Medical Communications, Six fig...
-
Six figure salary
- Account Manager– Medical Communications
-
(Negotiable - depending on experience)
Subscribe to our email news alerts
- FDA starts priority review of BMS Opdivo/Yervoy in first-line NSCLC
- NantKwest rockets on promising pancreatic cancer data
- Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
- Latecomer Lilly preps its IL-23 drug for Crohn’s disease
- J&J pushes to expand Imbruvica label after clinical success
- Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer
- J&J wins another label expansion for Darzalex in Europe
- EU grants conditional approval to Roche's lymphoma drug Polivy
- OPEN Health expands offering with the launch of a new Learning & Development specialist team
- Spotlight interview: 15 minutes on healthcare communications in gene therapy
- Lilly will aim for one $1bn-$5bn deal per quarter in 2020
- AZ’s Imfinzi scores orphan drug status in liver cancer
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Quick links
Infographics
